Global Actinic Keratosis Drugs Market 2017-2021
About Actinic Keratosis Drugs
Actinic keratosis is a pre-stage non-melanoma skin cancer caused by exposure to ultraviolet (UV) rays. Initially, the skin has a sandpaper-like texture with lesions. It can develop into squamous cell carcinoma, if not treated. The actinic keratosis drugs market includes nucleoside metabolic inhibitors, photosensitizers, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunomodulators.
Technavio’s analysts forecast the global actinic keratosis drugs market to grow at a CAGR of 3.32% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global actinic keratosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Actinic Keratosis Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global actinic keratosis drugs market: Almirall, GALDERMA, LEO Pharma, and Valeant.
Other Prominent Vendors in the market are: Biofrontera, Novartis, Perrigo, Promius Pharma, Taro Pharmaceutical Industries, TOLMAR Pharmaceuticals, and Vidac Pharma.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is novel drug delivery mechanisms. The advent of novel drug delivery systems such as microneedles will improve the efficacy and bioavailability of the already marketed formulations. Microneedling has evolved as an adjuvant therapy to the drug treatment available for actinic keratosis.”
According to the report, one driver in the market is high prevalence of actinic keratosis. Actinic keratosis develops mainly due to UV exposure. The lesions arising from actinic keratosis can lead to squamous cell carcinoma if left untreated. With the growing awareness of oncology, people believe in choosing causative treatment. This leads to a higher incidence rate of actinic keratosis treatment, which has been driving the market growth. The prevalence is high in individuals with fair skin and in regions with high exposure to the sun such as those near the equator. As per the NIH, the prevalence rate of actinic keratosis was estimated to be 40%-50% in the Caucasian population aged above 40 years.
Further, the report states that one challenge in the market is alternative treatment options. The availability of better alternative treatment modalities is the biggest challenge for the global actinic keratosis drugs market. The treatment of actinic keratosis through techniques such as cryotherapy and chemical peeling is more popular than treatment through drugs due to their better efficacy. Cryotherapy freezes the cells affected by actinic keratosis by applying liquid nitrogen to the area and thereby stops the disease growth. Considering that such quick therapies save on time and are convenient for patients, their popularity is only expected to grow over time.
Almirall, GALDERMA, LEO Pharma, Valeant, Biofrontera, Novartis, Perrigo, Promius Pharma, Taro Pharmaceutical Industries, TOLMAR Pharmaceuticals, and Vidac Pharma.